M. Thompson, J. Burgess, A. Naleway, Harmony Tyner, Sarang K. Yoon, J. Meece, Lauren E. W. Olsho, A. Caban-Martinez, A. Fowlkes, K. Lutrick, J. Kuntz, K. Dunnigan, M. Odean, K. Hegmann, Elisha L Stefanski, Laura J. Edwards, Natasha Schaefer-Solle, L. Grant, K. Ellingson, H. Groom, Tnelda Zunie, M. Thiese, L. Ivacic, Meredith G. Wesley, Julie Mayo Lamberte, Xiaoxiao Sun, Michael E Smith, A. Phillips, Kimberly D. Groover, Y. Yoo, J. Gerald, Rachel T. Brown, Meghan K. Herring, Gregory Joseph, S. Beitel, Tyson Morrill, Josephine Mak, P. Rivers, K. Harris, Danielle R. Hunt, Melissa L. Arvay, P. Kutty, A. Fry, M. Gaglani
MMWR. Morbidity and mortality weekly report, 2021
Messenger RNA (mRNA) BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccines have been shown to be effective in preventing symptomatic COVID-19 in randomized placebo-controlled Phase III trials (1,2); however, the benefits of these vaccines for preventing asymptomatic and symptomatic SARS-CoV-2 (the virus that causes COVID-19) infection, particularly when administered in real-world conditions, is less well understood. Using prospective cohorts of health care personnel, first responders, and other essential and frontline workers* in eight U.S. locations during December 14, 2020-March 13, 2021, CDC routinely tested for SARS-CoV-2 infections every week regardless of symptom status and at the onset of symptoms consistent with COVID-19-associated illness. Among 3,950 participants with no previous laboratory documentation of SARS-CoV-2 infection, 2,479 (62.8%) received both recommended mRNA doses and 477 (12.1%) received only one dose of mRNA vaccine.† Among unvaccinated participants, 1.38 SARS-CoV-2 infections were confirmed by reverse transcription-polymerase chain reaction (RT-PCR) per 1,000 person-days.§ In contrast, among fully immunized (≥14 days after second dose) persons, 0.04 infections per 1,000 person-days were reported, and among partially immunized (≥14 days after first dose and before second dose) persons, 0.19 infections per 1,000 person-days were reported. Estimated mRNA vaccine effectiveness for prevention of infection, adjusted for study site, was 90% for full immunization and 80% for partial immunization. These findings indicate that authorized mRNA COVID-19 vaccines are effective for preventing SARS-CoV-2 infection, regardless of symptom status, among working-age adults in real-world conditions. COVID-19 vaccination is recommended for all eligible persons.
Cited by 188 publications.
Field of study: Medicine